OB/GYN Clinical Alert – February 1, 2023
February 1, 2023
View Issues
-
#IUD on TikTok: An Analysis of Intrauterine Device-Related Content on Social Media
The top 100 videos on the social media platform TikTok were compiled and systematically analyzed for user demographics and video content. More videos had a negative tone, particularly those conveying patient experiences related to pain and informed consent.
-
New Treatments for Uterine Fibroids
In this prospective, open-label, single-arm trial of 149 individuals with heavy menstrual bleeding and uterine leiomyomas, daily relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) resulted in a mean menstrual blood loss reduction of 90%, and 70% of the participants achieved amenorrhea by the end of the 52-week period. Similar results were found for other arms of the trial among women who crossed over from placebo and relugolix-only therapy to relugolix combination therapy.
-
Provider Perceptions of Neonatal Survival for Fetuses Born at 22 Weeks of Gestation
Prognostic differences exist among neonatal and obstetric care providers when neonates are delivered at 22 weeks of gestation. However, there are no statistically significant differences in the gestational age at which providers recommend active treatment or antenatal corticosteroids.
-
Probiotics and Iron Intake in Pregnancy
In a randomized controlled trial, a significantly smaller decrease in serum ferritin was observed in pregnant women with the intake of a Lactiplantibacillus plantarum 299v supplement containing a low dose of iron, folic acid, and ascorbic acid than in the placebo group.